RBC Capital lowered the firm’s price target on Pharming (PHAR) to EUR 2 from EUR 2.15 and keeps an Outperform rating on the shares.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAR:
- Pharming Group Files 2024 Annual Report and Form 20-F
- Pharming price target raised to $39 from $30 at Oppenheimer
- Pharming Group’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- Pharming Group Reports Strong 2024 Revenue Growth
- Pharming Group Expands Stake in Abliva to 92.70%